PHTF2 Inhibitors
The chemical class of PHTF2 inhibitors encompasses a diverse array of compounds meticulously crafted to selectively target the RAF/MEK/ERK pathway, a pivotal signaling cascade with profound implications for the regulation of PHTF2. PHTF2, a transcription factor of significance, plays a crucial role in orchestrating cellular processes fundamental to cell proliferation, survival, and growth. The inhibitors within this class, including Sorafenib, Trametinib, Selumetinib, U0126, PD98059, GDC-0994, Cobimetinib, AZD6244, FR180204, SCH772984, AZD8330, and VX-11e, collectively exert their effects at distinct nodes of the RAF/MEK/ERK pathway, intricately modulating PHTF2-mediated gene expression.
Sorafenib, a prominent member of this class, exerts its influence at a specific point within the cascade. In contrast, Trametinib, Selumetinib, and U0126 target different components, contributing to a spectrum of modulatory actions. This multifaceted modulation highlights the intricate interplay between transcriptional control and cellular processes. The nuanced understanding facilitated by these inhibitors unravels the regulatory mechanisms dictating PHTF2's influence over genes associated with crucial cellular functions.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Sorafenib inhibits multiple kinases in the RAF/MEK/ERK pathway. By disrupting this pathway, it indirectly influences PHTF2, a transcription factor associated with cell proliferation. Inhibition of RAF prevents downstream signaling events, potentially impacting PHTF2-mediated gene expression. Sorafenib's modulation of the RAF/MEK/ERK pathway can alter cellular responses related to PHTF2's function, providing insight into its regulatory role in cell proliferation and potential therapeutic implications in diseases associated with dysregulated transcriptional control. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $114.00 $166.00 $947.00 | 19 | |
Trametinib is a MEK inhibitor that specifically targets MEK1 and MEK2 in the MAPK/ERK pathway. By inhibiting MEK, it indirectly influences PHTF2, a transcription factor implicated in cell survival. Disruption of the MAPK/ERK pathway alters downstream signaling, potentially impacting PHTF2-mediated gene expression. Trametinib's modulation of the MAPK/ERK pathway provides insights into the regulatory mechanisms of PHTF2 and its involvement in cell survival, contributing to our understanding of potential therapeutic strategies for diseases associated with dysregulated transcriptional control. | ||||||
Selumetinib | 606143-52-6 | sc-364613 sc-364613A sc-364613B sc-364613C sc-364613D | 5 mg 10 mg 100 mg 500 mg 1 g | $29.00 $82.00 $420.00 $1897.00 $3021.00 | 5 | |
Selumetinib inhibits MEK1/2 in the MAPK/ERK pathway. By disrupting this pathway, it indirectly influences PHTF2, a transcription factor linked to cell growth. Inhibition of MEK alters downstream signaling events, potentially impacting PHTF2-mediated gene expression. Selumetinib's modulation of the MAPK/ERK pathway offers insights into the regulatory mechanisms of PHTF2 and its role in cell growth, providing valuable information for understanding the molecular basis of diseases associated with dysregulated transcriptional control and exploring targeted therapeutic interventions. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 inhibits MEK1 in the MAPK/ERK pathway. By specifically targeting MEK, it indirectly influences PHTF2, a transcription factor linked to cell survival. Inhibition of MEK alters downstream signaling events, potentially impacting PHTF2-mediated gene expression. PD98059's modulation of the MAPK/ERK pathway offers insights into the regulatory mechanisms of PHTF2 and its role in cell survival, providing valuable information for understanding the molecular basis of diseases associated with dysregulated transcriptional control and exploring targeted therapeutic interventions. | ||||||
GDC0994 | 1453848-26-4 | sc-507297 | 10 mg | $130.00 | ||
GDC-0994 is a MEK1/2 inhibitor that disrupts the MAPK/ERK pathway. By inhibiting MEK, it indirectly influences PHTF2, a transcription factor associated with cell growth. Inhibition of MEK alters downstream signaling events, potentially impacting PHTF2-mediated gene expression. GDC-0994's modulation of the MAPK/ERK pathway provides insights into the regulatory mechanisms of PHTF2 and its involvement in cell growth, contributing to our understanding of potential therapeutic strategies for diseases associated with dysregulated transcriptional control. | ||||||
Cobimetinib | 934660-93-2 | sc-507421 | 5 mg | $270.00 | ||
Cobimetinib is a selective MEK inhibitor targeting MEK1 and MEK2 in the MAPK/ERK pathway. By inhibiting MEK, it indirectly influences PHTF2, a transcription factor linked to cell proliferation. Disruption of the MAPK/ERK pathway alters downstream signaling, potentially impacting PHTF2-mediated gene expression. | ||||||
ERK Inhibitor II, FR180204 | 865362-74-9 | sc-203945 sc-203945A sc-203945B sc-203945C | 1 mg 5 mg 10 mg 50 mg | $110.00 $165.00 $239.00 $942.00 | 45 | |
FR180204 is a selective ERK inhibitor targeting the downstream MAPK/ERK pathway. By inhibiting ERK, it indirectly influences PHTF2, a transcription factor associated with cell growth. Disruption of the MAPK/ERK pathway alters downstream signaling events, potentially impacting PHTF2-mediated gene expression. | ||||||
SCH772984 | 942183-80-4 | sc-473205 | 5 mg | $370.00 | 5 | |
SCH772984 is a selective ERK inhibitor that disrupts the MAPK/ERK pathway. By inhibiting ERK, it indirectly influences PHTF2, a transcription factor associated with cell proliferation. Inhibition of ERK alters downstream signaling events, potentially impacting PHTF2-mediated gene expression. SCH772984's modulation of the MAPK/ERK pathway provides insights into the regulatory mechanisms of PHTF2 and its involvement in cell proliferation, contributing to our understanding of potential therapeutic strategies for diseases associated with dysregulated transcriptional control. | ||||||
AZD8330 | 869357-68-6 | sc-364425 sc-364425A | 5 mg 10 mg | $255.00 $450.00 | ||
AZD8330 is a selective ERK inhibitor that disrupts the MAPK/ERK pathway. By inhibiting ERK, it indirectly influences PHTF2, a transcription factor linked to cell survival. Disruption of the MAPK/ERK pathway alters downstream signaling events, potentially impacting PHTF2-mediated gene expression. AZD8330's modulation of the MAPK/ERK pathway offers insights into the regulatory mechanisms of PHTF2 and its role in cell survival, providing valuable information for understanding the molecular basis of diseases associated with dysregulated transcriptional control and exploring targeted therapeutic interventions. | ||||||
VX-11e | 896720-20-0 | sc-507301 | 10 mg | $180.00 | ||
VX-11e is a selective ERK inhibitor that disrupts the MAPK/ERK pathway. By inhibiting ERK, it indirectly influences PHTF2, a transcription factor associated with cell growth. Inhibition of ERK alters downstream signaling events, potentially impacting PHTF2-mediated gene expression. | ||||||